PharmaShots | Incisive News in 3 Shots

Subscribe Now

IB-IIIA

AstraZeneca's Tagrisso (osimertinib) Receives the US FDA's BT Designation for the Adjuvant Treatment of Patients with Stage IB-IIIA EGFR-Mutated Lung Cancer

AstraZeneca's Tagrisso (osimertinib) Receives the US FDA's BT Designation for the Adjuvant Treatment of Patients with Stage IB-III...

July 30, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us